Biocompatibility of Amalgam vs Composite - A Review.


Journal

Oral health & preventive dentistry
ISSN: 1757-9996
Titre abrégé: Oral Health Prev Dent
Pays: Germany
ID NLM: 101167768

Informations de publication

Date de publication:
14 Mar 2022
Historique:
entrez: 21 3 2022
pubmed: 22 3 2022
medline: 23 3 2022
Statut: ppublish

Résumé

The Minamata Convention resulted in restrictions in the use of amalgam in daily dental practice. This opens up new discussions about the biocompatibility of amalgam, but also of composites as alternative materials. In the following review article, these issues will be discussed in more detail to provide dentists with a knowledge base for themselves and for communication with their patients. In addition to mercury in amalgam or monomers in composites, bisphenol A and nanoparticles generated during the grinding, polishing or removal of restorations must also be included in the biocompatibility evaluation. In laboratory tests, these substances cause toxic reactions, and bisphenol A also exhibits estrogen-like effects. However, it must be taken into account that the concentrations used in laboratory tests are much higher than in clinical practice. Thus, both amalgam and composite can be used in the general population. Nevertheless, for scientifically, politically and legally defined risk groups (e.g. dental personnel, allergic persons, pregnant or lactating women, children under 15 years of age, people with certain systemic diseases), indication restrictions and precautionary measures must be observed. The well-known amalgam discussion has taught us the importance of thorough and open risk communication with the patient.

Identifiants

pubmed: 35308016
pii: 2831749
doi: 10.3290/j.ohpd.b2831749
doi:

Substances chimiques

Benzhydryl Compounds 0
Biocompatible Materials 0
Phenols 0
Dental Amalgam 8049-85-2
Mercury FXS1BY2PGL
bisphenol A MLT3645I99

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-156

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH